Name: Bpc-157 Research Peptide
Brand: RetaLABS.is
SKU: bpc-157

Question 1

What is BPC-157 used for in research?

Accepted Answer

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a gastric protective protein sequence. Extensively studied in preclinical models, it has demonstrated effects across multiple tissue systems including tendon and ligament repair, gut mucosal healing, angiogenesis, and neuroprotection. Its proposed mechanisms operate through VEGF pathway modulation, FAK-paxillin signalling, and eNOS-mediated nitric oxide synthesis, all distinct from the incretin-class GLP-1 peptides, making it a separately useful tool for researchers studying cytoprotection and regeneration.

Published preclinical studies have investigated BPC-157 in models of Achilles tendon transection, MCL repair, intestinal inflammation, and peripheral nerve damage. Its stability in gastric juice gives it unusual bioavailability characteristics in animal models. RetaLABS stocks research-grade BPC-157 in 5mg, 10mg, and 20mg vials.

For mechanistic detail and research data, see the BPC-157 Research Guide. For reconstitution protocols, see the Peptide Reconstitution Guide.

Question 2

How does BPC-157 promote tissue healing?

Accepted Answer

Preclinical research suggests BPC-157 promotes tissue healing through several converging mechanisms. Upregulation of growth factor signalling appears central; studies indicate enhanced VEGF (vascular endothelial growth factor) expression, accelerating the formation of new blood vessels into repair zones. This is supported by evidence of increased EGF receptor pathway activity, which promotes epithelial and fibroblast proliferation. BPC-157 has also been shown to modulate the FAK-paxillin pathway, enhancing fibroblast spreading and migration into wound sites, a key early step in tissue remodelling. Modulation of nitric oxide synthesis through eNOS pathway interactions is a further proposed mechanism: NO signalling regulates vascular tone, platelet aggregation, and inflammatory cell recruitment, all of which influence repair kinetics. In tendon models specifically, BPC-157 has been associated with upregulated collagen type I gene expression. These intersecting mechanisms (angiogenesis, fibroblast activation, NO modulation, and growth factor signalling) provide multiple research angles for studying BPC-157's cytoprotective effects.

Question 3

How should BPC-157 be stored?

Accepted Answer

Lyophilised BPC-157 should be stored at −20°C, protected from light and moisture, to maintain maximum long-term stability. The lyophilised (freeze-dried) form is significantly more stable than reconstituted solution, as removal of water eliminates the primary route of hydrolytic and oxidative peptide degradation. Vials should remain sealed until use; once punctured, the lyophilised powder should be reconstituted and used promptly. For reconstitution, use bacteriostatic water or sterile saline. Inject the diluent slowly along the vial wall and gently swirl until dissolved. Do not shake. Once reconstituted, refrigerate at 2–8°C and use within four weeks. Avoid repeated freeze-thaw cycles on reconstituted solution, as cycling can promote peptide aggregation and reduce biological activity in research assays. For extended research programmes, keep the bulk vial lyophilised and frozen; reconstitute only the aliquot required for the current session.

Question 4

Is BPC-157 stable at room temperature?

Accepted Answer

Lyophilised BPC-157 has reasonable short-term stability at ambient temperatures, but extended exposure to room temperature should be avoided in research practice. The primary degradation pathways for peptides at room temperature include hydrolysis of peptide bonds, oxidation of sensitive residues, and microbial contamination if the vial seal is compromised. While the lyophilised form is more resilient than reconstituted solution, best practice is to minimise the time vials spend outside controlled storage. For routine laboratory handling, such as briefly bringing a vial to the bench for reconstitution, short exposure to ambient temperature is acceptable. Return the vial to −20°C storage promptly after use. For research requiring extended stability across assay runs, keep lyophilised vials at −20°C as the baseline condition and prepare fresh reconstituted aliquots from frozen stock rather than storing reconstituted solutions long-term at ambient temperature.

BPC-157 Research Peptides

BPC-157 20mg

BPC-157 / TB-500 Blend 10mg

BPC-157 10mg

BPC-157 5mg

Frequently Asked Questions